ORAMED PHARMACEUTICALS INC (ORMP) Stock Price & Overview

NASDAQ:ORMP • US68403P2039

Current stock price

3.42 USD
+0.03 (+0.88%)
Last:

The current stock price of ORMP is 3.42 USD. Today ORMP is up by 0.88%. In the past month the price increased by 0.29%. In the past year, price increased by 62.86%.

ORMP Key Statistics

52-Week Range1.82 - 3.76
Current ORMP stock price positioned within its 52-week range.
1-Month Range3.152 - 3.68
Current ORMP stock price positioned within its 1-month range.
Market Cap
136.116M
P/E
2.31
Fwd P/E
N/A
EPS (TTM)
1.48
Dividend Yield
7.31%

ORMP Stock Performance

Today
+0.88%
1 Week
+3.01%
1 Month
+0.29%
3 Months
+17.53%
Longer-term
6 Months +40.16%
1 Year +62.86%
2 Years +47.41%
3 Years +50.66%
5 Years -67.92%
10 Years -60.55%

ORMP Stock Chart

ORAMED PHARMACEUTICALS INC / ORMP Daily stock chart

ORMP Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ORMP. When comparing the yearly performance of all stocks, ORMP is one of the better performing stocks in the market, outperforming 86.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ORMP Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ORMP. ORMP has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ORMP Earnings

Next Earnings DateAug 12, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported$0.24
Revenue Reported
EPS Surprise %
Revenue Surprise %

ORMP Forecast & Estimates

6 analysts have analysed ORMP and the average price target is 6.38 USD. This implies a price increase of 86.4% is expected in the next year compared to the current price of 3.42.

For the next year, analysts expect an EPS growth of -186.56% and a revenue growth -100% for ORMP


Analysts
Analysts43.33
Price Target6.38 (86.55%)
EPS Next Y-186.56%
Revenue Next Year-100%

ORMP Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

ORMP Financial Highlights

Over the last trailing twelve months ORMP reported a non-GAAP Earnings per Share(EPS) of 1.48. The EPS increased by 924.83% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)43.85M
Industry RankSector Rank
PM (TTM) 2192.6%
ROA 19.89%
ROE 21.57%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)924.83%
Revenue 1Y (TTM)N/A

ORMP Ownership

Ownership
Inst Owners27.78%
Shares39.80M
Float32.16M
Ins Owners15.95%
Short Float %1.68%
Short Ratio3.19

About ORMP

Company Profile

ORMP logo image Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Company Info

IPO: 2002-04-01

ORAMED PHARMACEUTICALS INC

1185 Avenue Of The Americas, 3Rd Floor

New York City NEW YORK 10036 US

CEO: Nadav Kidron

Employees: 13

ORMP Company Website

ORMP Investor Relations

Phone: 16468441164

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What does ORMP do?

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.


What is the current price of ORMP stock?

The current stock price of ORMP is 3.42 USD. The price increased by 0.88% in the last trading session.


What is the dividend status of ORAMED PHARMACEUTICALS INC?

ORAMED PHARMACEUTICALS INC (ORMP) has a dividend yield of 7.31%. The yearly dividend amount is currently 0.


What is the ChartMill rating of ORAMED PHARMACEUTICALS INC stock?

ORMP has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


How many employees does ORAMED PHARMACEUTICALS INC have?

ORAMED PHARMACEUTICALS INC (ORMP) currently has 13 employees.


What is the market capitalization of ORMP stock?

ORAMED PHARMACEUTICALS INC (ORMP) has a market capitalization of 136.12M USD. This makes ORMP a Micro Cap stock.


Who owns ORAMED PHARMACEUTICALS INC?

You can find the ownership structure of ORAMED PHARMACEUTICALS INC (ORMP) on the Ownership tab.